Caris Life Sciences Files for IPO on Nasdaq

Caris Life Sciences has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering (IPO) of its Class A common stock, announced in a press release. The company plans to list its shares on the Nasdaq Global Select Market under the ticker symbol "CAI." The number of shares to be offered and the price range have not yet been determined.

The IPO will be managed by several leading financial institutions. JPMorgan Chase, Goldman Sachs, and BofA Securities will act as lead book-running managers, with Citigroup also participating as a book-running manager. Additional book-running managers include TD Cowen, Evercore ISI, and Guggenheim Securities, while BTIG and Wolfe | Nomura Alliance will serve as co-managers.

Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and molecular profiling. The company aims to transform healthcare through comprehensive molecular profiling and advanced AI and machine learning algorithms.